{"id":"W2088164570","doi":"10.3810/pgm.2014.10.2821","title":"Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes","year":2014,"lang":"en","type":"review","venue":"Postgraduate Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Eli Lilly (Canada); Hôtel-Dieu de Montréal","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Medicine; Exenatide; Metformin; Type 2 diabetes; Glucagon-like peptide 1 receptor; Glycemic; Sitagliptin; Liraglutide; Internal medicine; Nausea; Hypoglycemia; Clinical endpoint; Pharmacology; Diabetes mellitus; Insulin; Endocrinology; Clinical trial; Agonist; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009220464,0.0005347655,0.002922839,0.0002274614,0.00008354359,0.000007470904,0.0002910228,0.0001242231,0.00005737207],"category_scores_gemma":[0.0001796349,0.0002883093,0.0003774665,0.0004591508,0.0004444938,0.00002626412,0.000180614,0.0001767222,0.0000148575],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008326984,"about_ca_system_score_gemma":0.00005798375,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002523956,"about_ca_topic_score_gemma":0.000001598024,"domain_scores_codex":[0.9974103,0.00008850259,0.001153906,0.0004904558,0.0004484783,0.0004083378],"domain_scores_gemma":[0.9970939,0.0009786502,0.0007734069,0.0008216465,0.0001893232,0.0001430789],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001748183,0.0001581968,0.00003247301,0.06195158,0.003665783,0.000003961318,0.00006282716,2.700981e-7,0.000003763941,0.001694671,0.005247418,0.9270042],"study_design_scores_gemma":[0.003412602,0.001853479,0.0002906687,0.03941786,0.0173192,0.000002650365,0.00004952836,0.00003191365,0.00001022614,0.00004155214,0.9373601,0.0002102041],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001092265,0.9900821,0.00008753228,0.002543735,0.0005476616,0.004442489,0.0000597938,0.00003820779,0.002089265],"genre_scores_gemma":[0.0003154788,0.9931164,0.0009392369,0.0001444824,0.000275633,0.0001463473,0.0005923066,0.00007890822,0.004391152],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9321127,"threshold_uncertainty_score":0.9999569,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03907160391263062,"score_gpt":0.3232018956930605,"score_spread":0.2841302917804298,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}